CAT #: AVAILABLE IN LATE 2021

MyMRD® Myeloid Gene Panel Assay

  • Description of Test:

    The MyMRD – Myeloid Assay will be a sequencing-based assay designed to identify mutations (both SNVs and indels) within hotspots from a total of 53 genes. The assay will be capable of tracking minimal residual disease (MRD) by monitoring for relapse and refractory disease in patients who have been diagnosed with myeloid neoplasms, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and essential thrombocythemia (ET). For example, the MyMRD – Myeloid Assay will be able to identify at least one driver mutation in ≥95% of AML patients. The test will be indicated for use by qualified healthcare professionals in accordance with professional guidelines for clinical decision-making and in conjunction with other clinicopathological features.

     

  • Overview:

    After genomic DNA is extracted, indexed whole genome libraries will be hybridized with probes targeting mutation hotspots for next-generation duplex sequencing on the NovaSeq 6000. Coupling comprehensive gene coverage with enhanced depth of coverage and the power of our robust MyInformatics® variant calling and annotation software, the MyMRD – Myeloid Assay will confidently and reproducibly detect MRD from 1 in 500 cells down to 1 in 10,000 cells, depending on the number and type of mutations being tracked.

    Genes Targeted

    ASXL1 CTCF IDH1 NRAS SRSF2
    BCL2 DDX41 IDH2 PDS5B STAG2
    BCOR DHX15 IKZF1 PHF6 SUZ12
    BCORL1 DNMT3A JAK2 PTEN TET2
    BRAF EP300 KIT PTPN11 TP53
    BRINP3 ETNK1 KRAS RAD21 U2AF1
    CALR ETV6 MPL RUNX1 U2AF2
    CBL EZH2 MYD88 SETBP1 WT1
    CEBPA FLT3 NF1 SF3B1 ZRSR2
    CREBBP GATA1 NOTCH1 SMC1A
    CSF3R GATA2 NPM1 SMC3

Service Details

  • Indications for Testing:
    • Identify tumor-specific markers for post-treatment monitoring in:
      • Acute myeloid leukemia (AML)
      • Myelodysplastic syndrome (MDS)
      • Myeloproliferative neoplasms (MPN)
      • Essential Thrombocythemia (ET)
    • Monitor and evaluate for refractory and relapsed disease

Now Available

Our New Document Search Feature
SEARCH ⟶

Need Help Placing an Online Order?

Contact our Customer Service Team
CONTACT CUSTOMER SERVICE ⟶

Now Available

Our New Document Search Feature
SEARCH ⟶

Need Help Placing an Online Order?

Contact our Customer Service Team
CONTACT CUSTOMER SERVICE ⟶
LATEST NEWS

Invivoscribe Launches New Division for Drug Development ⟶

CONNECT